Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
90 hedge funds and large institutions have $240M invested in Inozyme Pharma in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 38 increasing their positions, 20 reducing their positions, and 19 closing their positions.
321% more call options, than puts
Call options by funds: $80K | Put options by funds: $19K
90% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 20
6.27% more ownership
Funds ownership: 80.74% → 87.02% (+6.3%)
1% more funds holding
Funds holding: 89 → 90 (+1)
5% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 19
37% less capital invested
Capital invested by funds: $382M → $240M (-$142M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$5.53M |
| 2 |
Millennium Management
New York
|
+$5.26M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$3.67M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.47M |
| 5 |
SC
Samlyn Capital
New York
|
+$2.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$3.35M |
| 2 |
EAM
Exome Asset Management
New York
|
-$2.09M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$1.71M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$1.34M |
| 5 |
SCM
Superstring Capital Management
New York
|
-$864K |
INZY Hedge Fund Activity: Q2 2024 in Review
90 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q2 2024, worth a combined $240M — down 37% from $382M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new INZY positions and 19 closed out — a net gain of 1 holder — while 38 added to existing stakes and 20 trimmed.
The largest buyer was Saturn V Capital Management, opening a new position worth an estimated $5.53M. The largest seller was Kennedy Capital Management, exiting entirely with an estimated $3.35M sold.
- 90 institutional investors held Inozyme Pharma (INZY) as of Q2 2024, up from 89 in Q1 2024.
- Funds reported $240M of Inozyme Pharma stock for Q2 2024, down 37% quarter-over-quarter.
- 20 funds opened new Inozyme Pharma positions in Q2 2024 and 19 closed out, a net change of +1 holder.
- The largest Inozyme Pharma buyer in Q2 2024 was Saturn V Capital Management, an estimated $5.53M added.
- The largest Inozyme Pharma seller in Q2 2024 was Kennedy Capital Management, an estimated $3.35M sold.
Based on aggregated 13F filings for Q2 2024.